Legence Corp. Class A Common stock
LGN
$68.33
-7.24%
Legence Corp is a provider of engineering, installation, and maintenance services for critical building systems, focusing on sectors like technology, life sciences, healthcare, and education. As a specialized player in the Engineering & Construction industry, it differentiates itself through expertise in complex HVAC, MEP, and building performance optimization. The current investor narrative centers on the company's rapid growth trajectory since its September 2025 IPO, with the stock surging 80% driven by strong operational momentum and a $24 million institutional investment, signaling confidence in its role in critical infrastructure build-outs.…
LGN
Legence Corp. Class A Common stock
$68.33
Related headlines
Investment Opinion: Should I buy LGN Today?
Rating: Buy. Thesis: Legence Corp offers a compelling growth story with 41.6% YoY revenue growth and strong analyst support, but investors must accept near-term margin volatility. The consensus analyst rating is Buy with an average target price of ~$127, implying 72% upside.
Supporting Evidence: Revenue growth of 41.6% YoY in Q4 2025 is well above industry averages. The P/S ratio of 1.00x is near the low end of its historical range (2.5-3.5x), suggesting potential undervaluation relative to sales. TTM free cash flow of $218.9 million provides a cash flow yield of ~4.8% (market cap $4.59B). The PEG ratio of 0.04 indicates the stock is cheap relative to expected earnings growth, assuming the $3.06 EPS estimate is achieved.
Risks & Conditions: The biggest risks are margin compression and high leverage. This Buy rating would be downgraded to Hold if gross margins fail to recover above 15% in the next two quarters, or if revenue growth decelerates below 20%. Upgrade to Strong Buy if the company reports a profitable quarter with positive net income. Overall, the stock appears undervalued on a P/S basis and relative to growth expectations, but fairly valued on forward earnings given the execution risk.
Sign up to view all
LGN 12-Month Price Forecast
Legence Corp is a high-growth, high-risk investment. The strong revenue momentum and low P/S ratio support a bullish stance, but the margin collapse and negative earnings temper confidence. The base case of 50% probability reflects a balanced view that margins will stabilize but not fully recover within 12 months. The bull case (30%) hinges on a rapid margin turnaround, while the bear case (20%) accounts for continued deterioration. I would upgrade to high confidence if gross margins exceed 15% in the next quarter, and downgrade to bearish if revenue growth falls below 20%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Legence Corp. Class A Common stock's 12-month outlook, with a consensus price target around $88.83 and implied upside of +30.0% versus the current price.
Average Target
$88.83
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$55 - $89
Analyst target range
Six analysts cover Legence, with a consensus leaning bullish. All recent ratings from firms like Stifel, Goldman Sachs, and RBC Capital are Buy or Outperform. The average estimated EPS for the next fiscal year is $3.06, with a low of $2.89 and high of $3.20. The average revenue estimate is $6.63 billion, implying significant growth. The implied upside from the current price of $73.66 to the average target (not provided directly) can be estimated using the forward P/E of 41.5x and average EPS of $3.06, giving a target of ~$127, representing about 72% upside. The high target of $3.20 EPS implies a price of ~$133, while the low target of $2.89 implies ~$120. The narrow range suggests strong conviction among analysts. The bullish consensus reflects confidence in the company's growth story and margin recovery.
Bulls vs Bears: LGN Investment Factors
Legence Corp presents a high-risk, high-reward profile. The bull case is anchored by 41.6% revenue growth, positive free cash flow, and strong analyst support with ~72% implied upside. However, the bear case highlights severe margin compression, net losses, and high leverage. The single most important tension is whether the company can reverse its margin decline and achieve profitability—if gross margins recover to 20%+ levels, the stock could re-rate significantly; if margins remain depressed, the high forward P/E of 41.5x may prove unsustainable. Currently, the bull case has stronger evidence given the growth trajectory and analyst conviction, but the margin risk is substantial.
Bullish
- Strong Revenue Growth: Revenue surged 41.6% YoY in Q4 2025 to $737.6 million, with TTM revenue accelerating from $505.9 million in Q1 2025 to $737.6 million in Q4 2025. This rapid growth is driven by demand for critical infrastructure in technology, life sciences, and healthcare sectors.
- Positive Free Cash Flow: TTM free cash flow is $218.9 million, providing a cushion despite net losses. This cash generation supports debt service and potential investments, with a PCF ratio of 9.95x indicating reasonable cash flow valuation.
- Analyst Consensus Bullish: All six analysts rate the stock Buy/Outperform, with an average EPS estimate of $3.06 for next fiscal year. The implied target price of ~$127 based on forward P/E of 41.5x offers ~72% upside from the current $73.66.
- Low PEG Ratio: The PEG ratio is 0.04, suggesting the stock is cheap relative to expected earnings growth. This implies the market is not fully pricing in the anticipated earnings turnaround, offering potential upside if estimates are met.
Bearish
- Net Losses and Margin Compression: Q4 2025 net loss was -$32.7 million, with gross margin collapsing from 21% in Q3 2025 to 6.4% in Q4 2025. The net margin of -4.4% and negative ROE of -15.2% highlight profitability challenges.
- High Debt-to-Equity Ratio: Debt-to-equity of 2.43 indicates significant financial leverage. While free cash flow provides some coverage, the high debt burden increases vulnerability to rising interest rates or economic downturns.
- Negative Trailing P/E: The trailing P/E is -42.6x due to negative earnings, making traditional valuation metrics unreliable. The forward P/E of 41.5x is elevated and relies on a significant earnings turnaround that may not materialize.
- Short-Term Price Weakness: The stock has declined 8.7% in the past month, underperforming the S&P 500 by 12.8%. This pullback from highs may indicate profit-taking or waning momentum, with the stock at 68.7% of its 52-week range.
LGN Technical Analysis
The stock is in a strong uptrend over the past year, with a 1-year price change of approximately 65.5% (6-month change). Currently trading at $73.66, it sits at 68.7% of its 52-week range ($26.96 low to $107.24 high), suggesting it is still in the upper half but has pulled back from the highs, indicating potential consolidation or a buying opportunity. The 1-month change of -8.7% contrasts with the 3-month change of +16.6%, showing short-term weakness after a strong rally. This divergence could signal a temporary pullback or profit-taking, but the 6-month trend remains bullish. The RSI is not provided, but the volume of 784,847 shares suggests active trading. The 52-week low of $26.96 provides strong support, while the 52-week high of $107.24 is the key resistance. A breakout above $107.24 would signal renewed momentum, while a breakdown below $70 could indicate further downside. Beta is not available, but the stock's volatility is evident from its 31.16% max drawdown, implying higher risk.
Beta
—
—
Max Drawdown
-33.2%
Largest decline past year
52-Week Range
$27-$107
Price range past year
Annual Return
—
Cumulative gain past year
| Period | LGN Return | S&P 500 |
|---|---|---|
| 1m | -20.5% | +1.0% |
| 3m | +3.4% | +7.9% |
| 6m | +53.2% | +8.5% |
| 1y | — | +20.1% |
| ytd | +52.9% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LGN Fundamental Analysis
Revenue has grown strongly, with the most recent quarterly revenue of $737.6 million (Q4 2025) up 41.6% year-over-year. The trailing twelve-month revenue trend shows acceleration from $505.9 million in Q1 2025 to $737.6 million in Q4 2025, driven by the Installation and Maintenance segment ($1.33 billion in annual revenue) and Engineering and Consulting ($514 million). This growth trajectory supports the investment case for a company capitalizing on demand for critical infrastructure. Despite revenue growth, the company reported a net loss of -$32.7 million in Q4 2025, with a gross margin of 6.4% (down from 21% in Q3 2025), indicating margin compression. The net margin was -4.4%, and the operating margin was 1.4%, suggesting profitability challenges. However, the company has positive free cash flow of $218.9 million TTM, and a current ratio of 1.57 indicates adequate liquidity. The debt-to-equity ratio of 2.43 is high, implying financial leverage, but the positive free cash flow provides some cushion. ROE is negative at -15.2%, reflecting the net loss.
Quarterly Revenue
$737642000.0B
2025-12
Revenue YoY Growth
+41.6%
YoY Comparison
Gross Margin
6.4%
Latest Quarter
Free Cash Flow
$218933000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LGN Overvalued?
Since net income is negative (TTM net loss), the P/E ratio is not meaningful (trailing P/E of -42.6). Therefore, we use the price-to-sales (P/S) ratio, which is 1.00x trailing. The forward P/E of 41.5x implies the market expects a significant earnings turnaround. The P/S ratio of 1.00x is below the industry average for Engineering & Construction (typically around 0.8-1.2x), suggesting it is fairly valued relative to sales. However, the EV/Sales of 2.29x is higher, reflecting debt. Historically, the P/S ratio has ranged from 2.5x to 3.5x over the past year, so the current 1.0x is near the low end of its historical range, indicating potential undervaluation if revenue growth continues. The PEG ratio of 0.04 suggests the stock is cheap relative to expected earnings growth, but this relies on forward estimates.
PE
-42.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -782x~72x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Legence's primary financial risk is its inability to translate rapid revenue growth into profitability. In Q4 2025, gross margin plummeted to 6.4% from 21% in Q3, leading to a net loss of -$32.7 million. The company carries a high debt-to-equity ratio of 2.43, and while TTM free cash flow is positive at $218.9 million, the negative net income and ROE of -15.2% indicate underlying operational inefficiencies. Revenue concentration in cyclical sectors like technology and life sciences adds vulnerability to sector-specific downturns.
Market & Competitive Risks: The stock trades at a forward P/E of 41.5x, which is elevated relative to the Engineering & Construction industry average of ~20x, implying high growth expectations. If the company fails to meet EPS estimates of $3.06, multiple compression could be severe. The 1-month relative strength of -12.8% vs. the S&P 500 suggests waning momentum, and the short ratio of 3.69 days indicates bearish positioning. Competitive pressures from larger players could also erode margins further.
Worst-Case Scenario: If gross margins continue to decline and the company fails to achieve profitability, the stock could fall to its 52-week low of $26.96, representing a -63.4% decline from the current price of $73.66. This scenario could be triggered by a major contract loss, cost overruns, or a broader economic slowdown reducing demand for critical infrastructure projects. The historical max drawdown of -31.16% provides a less severe but still significant downside reference.
FAQ
The primary risk is margin compression: gross margin fell from 21% in Q3 2025 to 6.4% in Q4 2025, and if it remains low, the company may continue to report net losses. Financial risk is high due to a debt-to-equity ratio of 2.43, though free cash flow of $218.9 million provides some buffer. Market risk includes the stock's high volatility (max drawdown -31.16%) and a short ratio of 3.69 days, indicating bearish sentiment. Company-specific risks include revenue concentration in cyclical sectors and dependence on fixed-price contracts that can lead to cost overruns.
The 12-month outlook is bullish with a base case target of $100-$120 (50% probability), assuming revenue growth moderates to 25-30% and margins stabilize. The bull case (30% probability) targets $120-$133 if margins recover to 20%+ and profitability is achieved. The bear case (20% probability) sees the stock falling to $27-$50 if margins deteriorate further. The most likely scenario is the base case, where the stock appreciates but faces headwinds from margin uncertainty. Key assumptions include gross margin recovery and sustained revenue growth above 25%.
Based on price-to-sales, LGN appears undervalued at 1.00x, near the low end of its historical range of 2.5-3.5x. However, the forward P/E of 41.5x is elevated, implying the market expects a significant earnings turnaround. The PEG ratio of 0.04 suggests the stock is cheap relative to expected growth, but this relies on achieving the $3.06 EPS estimate. Compared to the Engineering & Construction industry average P/S of ~1.0x, LGN is fairly valued on sales, but on earnings it is expensive given current losses. The valuation implies the market is pricing in a successful margin recovery.
Legence Corp offers a high-risk, high-reward opportunity. With 41.6% YoY revenue growth and a P/S ratio of 1.00x near historical lows, the stock appears undervalued relative to sales. Analysts are bullish, with an average target implying 72% upside. However, the company is unprofitable with a net loss of -$32.7 million in Q4 2025 and gross margins that collapsed to 6.4%. The stock is suitable for investors who can tolerate volatility and have a long-term horizon; it is not appropriate for conservative or income-focused investors. The biggest risk is that margins do not recover, leading to further downside.
LGN is better suited for long-term investment (3-5 years) given its growth stage and high volatility. The stock has a beta not provided, but its 31.16% max drawdown and 65.5% 6-month gain indicate significant price swings. Short-term trading is risky due to the recent 8.7% monthly decline and high short interest. The company does not pay a dividend, so total return depends on capital appreciation. A minimum holding period of 2-3 years is recommended to allow for margin recovery and earnings growth to materialize. Investors should monitor quarterly earnings closely for signs of improvement.